Abstract
Although tremendous progress has been made in recent years in skin cancer care for organ transplant recipients, significant gaps remain in data-driven clinical guidelines, particularly for the treatment and prevention of cutaneous squamous cell carcinoma (cSCC), the most common malignancy among this population. In this review, we aim to summarize current knowledge around the management of cSCC and highlight the most significant gaps in knowledge that continue to pose challenges in the delivery of skin cancer care for organ transplant recipients. We suggest future directions for research that will bridge existing gaps and establish evidence-driven guidelines for primary prevention, screening and treatment of cSCC in this high-risk patient population.
© 2017 British Association of Dermatologists.
MeSH terms
-
Antimetabolites, Antineoplastic / therapeutic use
-
Capecitabine / therapeutic use
-
Carcinoma, Squamous Cell / prevention & control
-
Carcinoma, Squamous Cell / therapy*
-
Health Behavior
-
Humans
-
Immunosuppression Therapy / adverse effects
-
Immunosuppression Therapy / methods
-
Immunosuppressive Agents / adverse effects
-
Keratoacanthoma / prevention & control
-
Keratoacanthoma / therapy
-
Neoplasm Metastasis
-
Niacinamide / therapeutic use
-
Organ Transplantation / adverse effects*
-
Papillomavirus Infections / prevention & control
-
Papillomavirus Vaccines
-
Photosensitivity Disorders / prevention & control
-
Photosensitivity Disorders / therapy
-
Quality of Life
-
Radiotherapy, Adjuvant
-
Retinoids / therapeutic use
-
Skin Neoplasms / prevention & control
-
Skin Neoplasms / therapy*
-
Sunlight / adverse effects
-
Transplant Recipients*
-
Vitamin B Complex / therapeutic use
Substances
-
Antimetabolites, Antineoplastic
-
Immunosuppressive Agents
-
Papillomavirus Vaccines
-
Retinoids
-
Vitamin B Complex
-
Niacinamide
-
Capecitabine